14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ATRS ranks #10857 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$3.42 (-0.29%)

Volume: 643k

Closed: Jan 19, 2022

Hollow Logo Score: -2.074

Antares Pharma Stock Forecast

$3.42 (-0.29%)

Volume: 643k

Closed: Jan 19, 2022

Score Hollow Logo -2.074

Antares Pharma Company Profile

100 Princeton South

Ewing NJ 08628




Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It also offers Elestrin gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; and Gelnique, an oxybutynin gel product for the treatment of overactive bladder. In addition, the company is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes; VIBEX QuickShot (QS) auto injectors for reducing risk of preterm birth; VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency; and Vibex QS M for the treatment of CNS indication. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals Inc. and Ferring B.V.; JCR Pharmaceuticals Co., Ltd.; Teva Pharmaceutical Industries, Ltd.; Actavis plc; Meda Pharmaceuticals, Inc.; and AMAG Pharmaceuticals, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE